(Q40299388)

English

Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm

scientific article published on 6 February 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Eduardo L. Franco

object named as

Eduardo L Franco

7

0 references

François Coutlée

4

object named as

François Coutlée

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Alex S Ferenczy

6

object named as

Alex Ferenczy

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Marie-Hélène Mayrand

10

object named as

Marie-Hélène Mayrand

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

14

object named as

Sam Ratnam

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Máire A Duggan

5

object named as

Máire A Duggan

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Michael Fung-Kee-Fung

8

object named as

Michael Fung-Kee-Fung

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Walter H Gotlieb

9

object named as

Walter Gotlieb

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

11

object named as

Meg McLachlin

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

author name string

Joseph E Tota

1

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

James Bentley

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Jennifer Blake

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Joan Murphy

12

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

language of work or name

0 references

publication date

6 February 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Preventive Medicine

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

98

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

5-14

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Cervical cancer trends in the United States: a 35-year population-based analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Offering Self-Sampling Kits for HPV Testing to Reach Women Who Do Not Attend in the Regular Cervical Cancer Screening Program

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Liquid compared with conventional cervical cytology: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Trends of cervical cancer mortality in the member states of the European Union

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: Implications for vaginal self-collection

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

The health and economic effects of HPV DNA screening in The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Incidence Trends of Adenocarcinoma of the Cervix in 13 European Countries

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Recommendations on screening for cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Risk assessment to guide the prevention of cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Overview of the European and North American studies on HPV testing in primary cervical cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Sociodemographic factors associated with cervical cancer screening coverage and follow-up of high grade abnormal results in a population-based cohort

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Cervical cancer screening following prophylactic human papillomavirus vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Declining death rates reflect progress against cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Risk estimation for the next generation of prevention programmes for cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Canadian cancer screening disparities: a recent historical perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Increased cervical cancer risk associated with screening at longer intervals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Low rates of cervical cancer screening among urban immigrants: a population-based study in Ontario, Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Human papillomavirus and Papanicolaou tests to screen for cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

HPV immunisation and cervical screening--confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Self-collected HPV testing improves participation in cervical cancer screening: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Optimizing technology for cervical cancer screening in high-resource settings

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

HPV screening for cervical cancer in rural India

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Screening and adenocarcinoma of the cervix.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

American Cancer Society guideline for the early detection of cervical neoplasia and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Human papillomavirus and cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Human papillomavirus testing in the prevention of cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Women's intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Process of care failures in invasive cervical cancer: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

The road ahead for cervical cancer prevention and control

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Human papillomavirus vaccines: WHO position paper, October 2014-Recommendations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

The ATHENA human papillomavirus study: design, methods, and baseline results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Monitoring disease burden and preventive behavior with data linkage: cervical cancer among aboriginal people in Manitoba, Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.YPMED.2016.11.029

7 January 2021

Identifiers

10.1016/J.YPMED.2016.11.029

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40299388&oldid=1894196535"